2-chloro-n(6)cyclopentyladenosine has been researched along with hmr 1098 in 1 studies
Studies (2-chloro-n(6)cyclopentyladenosine) | Trials (2-chloro-n(6)cyclopentyladenosine) | Recent Studies (post-2010) (2-chloro-n(6)cyclopentyladenosine) | Studies (hmr 1098) | Trials (hmr 1098) | Recent Studies (post-2010) (hmr 1098) |
---|---|---|---|---|---|
252 | 0 | 43 | 58 | 0 | 5 |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 1 (100.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fox, JE; French, RJ; Kanji, HD; Light, PE | 1 |
1 other study(ies) available for 2-chloro-n(6)cyclopentyladenosine and hmr 1098
Article | Year |
---|---|
Distinct myoprotective roles of cardiac sarcolemmal and mitochondrial KATP channels during metabolic inhibition and recovery.
Topics: Adenosine; Adenosine Triphosphate; Animals; ATP-Binding Cassette Transporters; Benzamides; Calcium; Cell Hypoxia; Cell Line; Cell Survival; Cells, Cultured; Decanoic Acids; Dose-Response Relationship, Drug; Enzyme Activation; Heart Ventricles; Humans; Hydroxy Acids; Ischemic Preconditioning, Myocardial; KATP Channels; Luminescent Proteins; Membrane Potentials; Mitochondria; Myocardium; Oxygen; Potassium Channels; Potassium Channels, Inwardly Rectifying; Purinergic P1 Receptor Agonists; Purinergic P1 Receptor Antagonists; Rats; Recombinant Fusion Proteins; Sarcolemma; Time Factors; Ventricular Function; Xanthines | 2001 |